Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae : an economic evaluation from a hospital perspective

Abstract

The cost estimates that we present suggest that CPE outbreaks are highly costly.

Healthcare‐acquired infections: prevention strategies

“…For example, a KPC outbreak in the UK involving 40 patients over three sites cost over $AUD 1.5 million to control. 25 If solutions to prevent CPE nosocomial infection are to be found, they relate to the early recognition and containment of CPE spread through integrated surveillance, optimised cleaning, and a collective drive to regulate and minimise inappropriate antibiotic use.…”

The polymyxin derivative NAB739 is synergistic with several antibiotics against polymyxin-resistant strains of Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii

“…Carbapenems have become last-line drugs against extensively drugresistant (XDR) strains of Enterobacteriaceae and Acinetobacter baumannii. Now, the global dissemination of strains carrying carbapenemases has resulted in limited therapeutic options [1][2][3][4][5][6]. Low serum and urine levels shadow the use tigecycline [5], whereas ceftazidime-avibactam (CZA) is confronted by emerging resistance [6] and is not effective against enzymes that belong to the metallo-β-lactamase group.…”

Reduced Incubation Time of the Modified Carbapenem Inactivation Test and Performance of Carbapenem Inactivation in a Set of Carbapenemase-Producing Enterobacteriaceae with a High Proportion of bla IMP Isolates

“…Infections caused by carbapenemase-producing Enterobacteriaceae (CPE) result in increased patient mortality and morbidity (1,2). This can result in significant excess health care-associated costs for patient management and also for outbreak control (3,4). The rapid identification of transmissible resistance genes, particularly those that encode carbapenemases, is of critical importance to help prevent the spread of these organisms within health care settings, as well as to guide individual therapy and shape public health responses.…”